idw – Informationsdienst Wissenschaft
Nachrichten, Termine, Experten
Nachrichten, Termine, Experten
idw - Informationsdienst
Wissenschaft
New hope: MHH researchers are mobilising the immune system's defence against tumour cells within just two weeks using a two-phase vaccination regimen.
Our body's own defence system not only clears away bacteria and viruses, it can also fight cancer. However, not all tumour cells are easily recognisable by the immune system. In addition, they are constantly changing and camouflaging themselves to evade the defence system. In order to treat tumour diseases better and more successfully, medical research is focusing on so-called therapeutic cancer vaccines. In this form of immunotherapy, people who already have cancer are vaccinated. It works in a similar way to vaccinations against pathogens and teaches the immune system to recognise tumour cells by certain typical characteristics – known as tumour antigens – and kill them.
One approach is to remove highly specialised immune cells from cancer patients and load them with tumour antigens outside the body. After these dendritic cells are injected back into the body, they can trigger and regulate antigen-specific immune responses. In another approach, the vaccine, which is protein-based or peptide-based, contains only the protein of the tumour antigen or at least parts of it. This synthetic method is faster, cheaper and less complex. The problem with both methods is that the immune response triggered is often rather weak and the vaccination must be repeated frequently to activate the immune cells.
A research team led by associate professor Dr. Thomas Wirth and Dr. Dimitrij Ostroumov from the Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology at Hannover Medical School (MHH) has now developed a new power vaccine. With this therapeutic immunotherapy, just two injections under the skin are enough to effectively mobilise the immune system against the tumour within only 14 days. The work has been published in the journal Cellular and Molecular Immunology.
Vaccination takes place in two phases
Researchers have been working for 15 years to improve cancer vaccines. ‘The key lies in the dendritic cells,’ says Dr. Wirth. These cells are part of the innate immune system and constantly scan our bodies for viruses, bacteria and tumour cells. If they recognise structures as foreign or different, they absorb them completely or partially, eating them, so to speak. As antigen-presenting cells, they are able to break down the foreign cell components into smaller pieces and then present them as peptides on their own cell surface. These mini-proteins show the specific T cells of our acquired immune system how to recognise the foreign structures, thereby activating the targeted immune response.
To achieve this as quickly and effectively as possible, the researchers opted for a two-phase vaccination schedule: a basic vaccination followed by a booster vaccination. In such heterologous prime-boost vaccines, the same antigens are injected into the organism twice in different compositions. In this case, a single antigen peptide specifically produced by the tumour cells was sufficient to activate the dendritic cells directly in the body. However, because the peptide alone does not trigger a sufficiently strong immune response, the researchers added a so-called agonist in both vaccination phases to further activate the immune cells in the body. ‘For the primary immunisation, we package the peptide with the immune activator in a lipid shell,’ explains Dr. Wirth. This drives the dendritic cells in the body to present the tumour antigen to the specific T cells so that they can recognise and attack the tumour. The liposomes used for primary immunisation were developed as part of a collaboration in the Netherlands. ‘When boosting a week later, we also add an antibody that acts as an additional stimulator to ensure that the T cells directed against the tumour multiply ultra-fast.’
Exceptional enhancement of the T-cell response
The vaccination regimen was tested in a mouse model for colon cancer. The effect astonished even the researchers. ‘After only two vaccinations, we observed an extremely strong immune response that led to a complete regression of the tumour,’ emphasises Dr. Ostroumov. ‘Our experiments not only show that liposomes can be used as peptide carriers without any problems, but also confirm the extraordinary enhancement of the T-cell response by stimulating antibodies in the heterologous vaccination regimen.’ The rapid production of the vaccines and the early anti-tumour effect mean an extreme time advantage and thus also a survival advantage for people with cancer.
Another advantage of the vaccination regimen is that it is universal: the peptide building block can be exchanged like in a construction kit and adapted to the respective requirements. ‘On the one hand, we can tailor the peptide to the genetic profile of the tumour, i.e. produce personalised vaccines that are individually tailored to each patient,’ says Dr. Wirth. ‘On the other hand, the peptide does not even have to be a tumour antigen, but can also carry other information, such as for the detection of parasites, bacteria or viruses.’ However, there is still a long way to go before the vaccine becomes part of standard care. The next step would be clinical trials to prove its efficacy and safety for use in humans.
SERVICE
The original paper, ‘Sequential STING and CD40 agonism drives massive expansion of tumour-specific T cells in liposomal peptide vaccines,’ can be found here: https://www.nature.com/articles/s41423-024-01249-4
For further information, please contact associate professor Dr. Thomas Wirth, wirth.thomas@mh-hannover.de.
New two-phase cancer vaccine boosts the immune system.
Copyright: AI-generated by Karin Kaiser/MHH.
Merkmale dieser Pressemitteilung:
Journalisten
Medizin
überregional
Forschungsergebnisse, Wissenschaftliche Publikationen
Englisch
Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.
Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).
Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.
Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).
Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).
